Evaluating Stenting in Intracranial Arterial Stenosis

Managing symptomatic intracranial arterial stenosis remains a formidable challenge in modern stroke neurology. Clinicians frequently encounter severe intracranial narrowing that increases recurrent ischemic stroke risk despite medical therapy. Percutaneous transluminal angioplasty and stenting was developed to restore cerebral blood flow rapidly. However, clinical trials comparing endovascular stenting with aggressive medical management have shown conflicting or concerning safety results. Additionally, arterial anatomy varies significantly across cerebral territories, which might influence procedural outcomes. Consequently, researchers conducted a preplanned pooled individual patient data analysis to determine whether therapeutic efficacy depends on the specific vessel affected. This evaluation focused on the internal carotid artery, middle cerebral artery, vertebral artery, and basilar artery. By synthesizing individual patient data, the study sought to clarify whether specific anatomical subgroups derive benefit from endovascular intervention. Ultimately, these findings help clinicians tailor treatment strategies based on vascular location. Understanding vessel-specific risks allows care teams to refine patient selection and minimize avoidable procedural complications in high-risk patients.

Pooled Analysis Methodology Across Major Clinical Trials

To establish robust evidence, investigators pooled individual patient data from two seminal randomized controlled trials. Specifically, they combined data from the SAMMPRIS trial and the CASSISS trial. This combined cohort provided a rigorous dataset comprising 809 total participants diagnosed with symptomatic high-grade intracranial narrowing. Among these individuals, 400 patients underwent percutaneous angioplasty and stenting alongside medical therapy. Conversely, 409 patients received aggressive medical management alone. Furthermore, the primary study outcome was a composite endpoint evaluating major adverse events. This endpoint included any stroke or death within 30 days after enrolment. Additionally, it tracked ischemic stroke within the territory of the qualifying artery from day 31 through one year. The research team applied an intention-to-treat methodology to preserve randomized comparison integrity. Hazard ratios with 95% confidence intervals provided precise risk estimates across all arterial subcategories. Consequently, this analytical approach delivered unparalleled statistical power to evaluate vascular outcomes across distinct cerebral territories.

Basilar Artery Findings in Intracranial Arterial Stenosis

The analysis revealed crucial differences in treatment efficacy when examining specific vascular locations. Most notably, patients presenting with symptomatic basilar artery stenosis experienced significantly worse outcomes following endovascular stenting. Within this subgroup, the primary outcome occurred in 17.17% of patients assigned to stenting compared with only 7.77% in the medical therapy group. Consequently, stenting was associated with a more than two-fold increase in primary endpoint events, yielding a hazard ratio of 2.38. This statistically significant divergence underscores the heightened hazard of endovascular manipulation within the posterior circulation. Perforator vessel occlusion and localized brainstem ischemia frequently complicate basilar artery interventions. Therefore, stenting in this anatomical location poses substantial short-term and long-term stroke risks. Without substantial technological improvements to mitigate procedural hazards, endovascular intervention offers limited clinical utility for basilar artery lesions. Clinicians must exercise extreme caution when considering invasive options for basilar narrowing, prioritizing aggressive medical management instead.

Outcomes in Anterior Circulation Territories

In contrast to the basilar artery, anterior circulation territories demonstrated different risk profiles. Patients presenting with internal carotid artery stenosis experienced primary event rates of 26.67% in the stenting cohort and 16.67% in the medical group. Although stenting numerical rates appeared higher, this difference did not achieve statistical significance, yielding a hazard ratio of 1.68. Similarly, outcomes among patients with middle cerebral artery stenosis showed no significant advantage for endovascular intervention. In the middle cerebral artery subgroup, primary endpoint rates reached 8.28% with stenting and 9.79% with medical therapy. This yielded a hazard ratio of 0.85, indicating comparable primary outcome frequencies between both strategies. Consequently, endovascular stenting provided no clear clinical superiority over optimal medication regimens in anterior circulation vessels. Furthermore, peri-procedural risks associated with stenting offset potential long-term hemodynamic benefits. Thus, medical therapy remains the primary therapeutic strategy for symptomatic internal carotid and middle cerebral artery narrowing.

Vertebral Artery Outcomes and Comparative Safety

Evaluation of the vertebral artery territory revealed findings similar to those observed in anterior circulation lesions. Specifically, patients with symptomatic intracranial vertebral artery stenosis demonstrated no statistically significant benefit from endovascular stenting compared with medical management. Primary outcome events occurred in 9.52% of vertebral artery stenting patients and 10.71% of medically managed patients. This yielded a hazard ratio of 0.91, demonstrating nearly equivalent long-term outcomes between the two treatment groups. Consequently, routine endovascular intervention does not superiorly protect against recurrent ischemic stroke in vertebral artery lesions. Across all four qualifying arteries, stenting failed to show a statistically significant reduction in primary ischemic events. Furthermore, the elevated procedural complication rates associated with stent placement frequently negated potential long-term arterial patency benefits. Therefore, medical therapy incorporating dual antiplatelet agents, aggressive lipid lowering, and strict blood pressure control continues to be the safest and most effective strategy across diverse vascular beds.

Clinical Recommendations and Future Neurological Practice

This pooled individual patient data analysis provides definitive guidance for stroke neurologists and neuro-interventionalists. Stenting significantly increases stroke risk in basilar artery stenosis, while offering no significant advantage in internal carotid, middle cerebral, or vertebral artery stenosis. Consequently, clinicians should reserve stenting for highly selected, medically refractory cases after exhaustive non-invasive therapy. Moreover, these trial findings emphasize the paramount importance of maximizing medical therapy in routine practice. High-dose statins, targeted antiplatelet therapy, and rigorous lifestyle interventions form the cornerstone of recurrent stroke prevention. Future advances in stent design or microcatheter technology may eventually lower peri-procedural complications. However, current device technology does not justify routine endovascular stenting over medical care. Furthermore, multidisciplinary stroke teams must carefully weigh vessel-specific risks prior to attempting interventional procedures. By prioritizing evidence-based medical regimens, healthcare providers can optimize long-term clinical outcomes while avoiding preventable procedural harms in complex cerebrovascular disease.

Frequently Asked Questions

What did the pooled analysis reveal regarding basilar artery stenting?

The pooled analysis revealed that stenting for symptomatic basilar artery stenosis significantly increased the primary outcome risk compared with medical therapy alone (17.17% vs 7.77%). Consequently, stenting carries a hazard ratio of 2.38 in this territory, highlighting elevated procedural stroke and mortality risks.

Does intracranial stenting show benefit in middle cerebral artery stenosis?

No, stenting showed no statistically significant advantage over medical therapy alone for middle cerebral artery stenosis. Primary outcome rates were 8.28% in the stenting group and 9.79% in the medical therapy group, demonstrating that aggressive medical management remains equally effective without procedural hazards.

What is the current standard of care for symptomatic intracranial arterial stenosis?

Aggressive medical therapy remains the standard of care for symptomatic intracranial arterial stenosis across all major qualifying arteries. This regimen includes intensive antiplatelet therapy, aggressive blood pressure control, and high-intensity lipid-lowering therapy to prevent recurrent stroke without incurring peri-procedural risks.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Refer to the latest local and national guidelines for clinical practice.

References

1. Li T et al. Stenting for symptomatic intracranial arterial stenosis with different qualifying arteries: a preplanned pooled individual patient data analysis. Stroke Vasc Neurol. 2025 Aug 26. doi: 10.1136/svn-2024-003532. PMID: 39455066.


2. Gao P et al. China Angioplasty and Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS): a new, prospective, multicenter, randomized controlled trial in China. Interv Neuroradiol. 2015;21(2):196-204.